BIVM: A Potential Drug Target and Biomarker for Melanoma (G54841)

Target Name: BIVM

NCBI ID: G54841

BIVM

Other Name(s): BIVM_HUMAN | basic, immunoglobulin-like variable motif containing | BIVM variant 1 | Basic immunoglobulin-like variable motif-containing protein | Basic, immunoglobulin-like variable motif containing, transcript variant 1 | Basic immunoglobulin-like variable motif-containing protein (isoform a)

BIVM: A Potential Drug Target and Biomarker for Melanoma

Melanoma is one of the most aggressive and deadly forms of skin cancer, with a high incidence of recurrence and poor prognosis. Despite advances in surgical and radiation treatments, the survival rate for melanoma remains poor, with a five-year survival rate of only around 15%. Therefore, there is a strong need for new treatments and biomarkers to improve outcomes for melanoma patients.

One potential drug target for melanoma is BIVM (尾-intraprolactone), a metabolite of the drug Valsartan. BIVM has been shown to have anti-inflammatory and apoptotic effects in melanoma cells, and has been shown to reduce the growth of melanoma tumors in cell culture and animal models.

In addition to its potential therapeutic benefits, BIVM is also a potential biomarker for melanoma. The high sensitivity and specificity of BIVM make it an attractive candidate for use as a diagnostic marker for melanoma.

BIVM works by inhibiting the production of melanoma-associated suppressor cells (MASCs), which are a type of cancer stem cell that can give rise to new tumors. MASCs are a common complication in melanoma, and have been shown to contribute to the development and progression of melanoma. By inhibiting MASCs, BIVM has been shown to reduce the growth of melanoma tumors in cell culture and animal models.

In addition to its anti-inflammatory and apoptotic effects, BIVM has also been shown to have pro-inflammatory effects in melanoma cells. This is important because it gives rise to the idea that BIVM may have a potential mechanism of action that is different from those of traditional anti-inflammatory drugs.

The use of BIVM as a drug target for melanoma is an exciting area of research, and holds great promise for the treatment of this aggressive and deadly form of skin cancer. Further studies are needed to fully understand the anti-inflammatory and apoptotic effects of BIVM in melanoma cells, and to determine the best way to use it as a treatment.

Protein Name: Basic, Immunoglobulin-like Variable Motif Containing

The "BIVM Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BIVM comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets